{"id":390886,"date":"2017-10-13T00:00:00","date_gmt":"2017-10-13T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0004-2017-biopharma-multiple-sclerosis-disease-landscape-and-forecast-g7-2017\/"},"modified":"2026-05-01T23:42:14","modified_gmt":"2026-05-01T23:42:14","slug":"dlsfcg0004-2017-biopharma-multiple-sclerosis-disease-landscape-and-forecast-g7-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0004-2017-biopharma-multiple-sclerosis-disease-landscape-and-forecast-g7-2017\/","title":{"rendered":"Multiple Sclerosis | Disease Landscape and Forecast | G7 | 2017"},"content":{"rendered":"<p>The maturing but highly lucrative market for\u00a0<abbr data-original-title=\"multiple sclerosis\" title=\"\">MS<\/abbr><abbr data-original-title=\"disease-modifying therapy\" title=\"\">DMT<\/abbr>s continues to fragment as new entrants propel ongoing shifts in a complicated treatment algorithm. Roche\/Genentech\u2019s Ocrevus will intensify competition in relapsing\u00a0<abbr data-original-title=\"multiple sclerosis\" title=\"\">MS<\/abbr>\u00a0and will stoke the perennial debate about early intervention with high efficacy drugs. Meanwhile, Ocrevus is set to meaningfully expand treatment in the underserved progressive\u00a0<abbr data-original-title=\"multiple sclerosis\" title=\"\">MS<\/abbr>\u00a0population. Separately, the looming entry of additional generics will begin\u00a0a shift in this high-cost market and limit the market potential for follow-on brands as reimbursement authorities race to reign in healthcare costs. Against this complex backdrop, drug developers have resharpened their focus on developing neuroprotective or reparative treatments in\u00a0<abbr data-original-title=\"multiple sclerosis\" title=\"\">MS<\/abbr>\u2014now the \u201cnext frontier\u201d in a market replete with solid anti-inflammatory options. Understanding these intersecting forces will be key to the success of current and future players in this evolving market.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>What is the commercial outlook for Ocrevus compared with other potent\u00a0<abbr data-original-title=\"disease-modifying therapy\" title=\"\">DMT<\/abbr>s? What impact will Ocrevus have in the progressive\u00a0<abbr data-original-title=\"multiple sclerosis\" title=\"\">MS<\/abbr>\u00a0market, specifically?<\/li>\n<li>How will generic competition shape the\u00a0<abbr data-original-title=\"multiple sclerosis\" title=\"\">MS<\/abbr>\u00a0market, and when will it occur?<\/li>\n<li>What clinical roles will entrenched platform injectables, current and next-generation orals, and\u00a0<abbr data-original-title=\"monoclonal antibody\" title=\"\">MAb<\/abbr>s play in the evolving\u00a0<abbr data-original-title=\"multiple sclerosis\" title=\"\">MS<\/abbr>\u00a0treatment algorithm?<\/li>\n<li>What do\u00a0<abbr data-original-title=\"key opinion leader\" title=\"\">KOL<\/abbr>s think about Biogen\u2019s potentially ground-breaking remyelinating therapy opicinumab?<\/li>\n<\/ul>\n<p><strong>Product Description:<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390886","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-sclerosis","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390886","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390886\/revisions"}],"predecessor-version":[{"id":576810,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390886\/revisions\/576810"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390886"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}